EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-21.3% YoY

Gross Profit

$7M80.3% margin

Operating Income

-$23M-250.0% margin

Net Income

-$23M-251.7% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+18.5%

Cash Flow

Operating Cash Flow

$57M

Free Cash Flow

$57M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$176M

Total Liabilities

$118M

Stockholders' Equity

$57M

Cash & Equivalents

$140M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$12M	-21.3%
Gross Profit	$7M	$10M	-25.6%
Operating Income	-$23M	-$19M	-18.4%
Net Income	-$23M	-$19M	-18.1%

Revenue Segments

Product

$5M58%

License And Collaboration Agreement

$4M40%

Royalty

$235,0003%

EYPT Q2 2023 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena